The FDA Approves a Pill That Doubles Survival for Late-Stage Pancreatic Cancer Patients

The FDA has approved a twice-daily pill that roughly doubled survival time for patients with late-stage pancreatic cancer after chemotherapy stopped working. Pancreatic cancer has long carried one of the worst prognoses in oncology. The agency moved on the approval immediately following trial results.